MedTrace Logo

Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

NCT01313962 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2012-01-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and pharmacokinetic profile of flufirvitide-3 nasal spray in healthy subjects.

Conditions

Interventions

DRUG

Flufirvitide-3 0.05 mg single dose

Nasal Spray

DRUG

Flufirvitide-3, 0.1 mg single dose

Nasal spray

DRUG

Flufirvitide-3, 0.2 mg single dose

nasal spray

DRUG

Flufirvitide-3, 0.4 mg single dose

Nasal spray

OTHER

Placebo

Nasal spray

Sponsors & Collaborators

  • Autoimmune Technologies, LLC

    lead INDUSTRY

Principal Investigators

  • Sam Hopkins, PhD · Autoimmune Technologies, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01313962 on ClinicalTrials.gov